These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 34884681

  • 1. Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation.
    Meier-Schiesser B, Mellett M, Ramirez-Fort MK, Maul JT, Klug A, Winkelbeiner N, Fenini G, Schafer P, Contassot E, French LE.
    Int J Mol Sci; 2021 Nov 28; 22(23):. PubMed ID: 34884681
    [Abstract] [Full Text] [Related]

  • 2. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
    Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW, Muller GW, Stirling DI, Chopra R.
    Cell Signal; 2014 Sep 28; 26(9):2016-29. PubMed ID: 24882690
    [Abstract] [Full Text] [Related]

  • 3. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M, Papp K.
    BioDrugs; 2015 Oct 28; 29(5):327-39. PubMed ID: 26481941
    [Abstract] [Full Text] [Related]

  • 4. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
    Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG.
    J Drugs Dermatol; 2018 Aug 01; 17(8):835-840. PubMed ID: 30124722
    [Abstract] [Full Text] [Related]

  • 5. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
    Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung YF, Baillie GS, Houslay MD, Man HW, Muller GW, Stirling DI.
    Br J Pharmacol; 2010 Feb 01; 159(4):842-55. PubMed ID: 20050849
    [Abstract] [Full Text] [Related]

  • 6. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
    Schafer P.
    Biochem Pharmacol; 2012 Jun 15; 83(12):1583-90. PubMed ID: 22257911
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM.
    Drugs; 2017 Mar 15; 77(4):459-472. PubMed ID: 28213862
    [Abstract] [Full Text] [Related]

  • 10. [Phosphodiesterase 4 inhibitors in dermatology : Role in the treatment of skin diseases].
    Schmidt MF, Albuscheit N, Yazdi AS.
    Dermatologie (Heidelb); 2024 Oct 15; 75(10):791-797. PubMed ID: 39212723
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Maier C, Ramming A, Bergmann C, Weinkam R, Kittan N, Schett G, Distler JHW, Beyer C.
    Ann Rheum Dis; 2017 Jun 15; 76(6):1133-1141. PubMed ID: 28209630
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.
    Li H, Fan C, Feng C, Wu Y, Lu H, He P, Yang X, Zhu F, Qi Q, Gao Y, Zuo J, Tang W.
    Br J Pharmacol; 2019 Jul 15; 176(13):2209-2226. PubMed ID: 30883697
    [Abstract] [Full Text] [Related]

  • 17. Apremilast for the treatment of psoriasis.
    Chimenti MS, Gramiccia T, Saraceno R, Bianchi L, Garofalo V, Buonomo O, Perricone R, Chimenti S, Chiricozzi A.
    Expert Opin Pharmacother; 2015 Jul 15; 16(13):2083-94. PubMed ID: 26243735
    [Abstract] [Full Text] [Related]

  • 18. Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4.
    Wegesser T, Coppi A, Harper T, Paris M, Minocherhomji S.
    Regul Toxicol Pharmacol; 2021 Oct 15; 125():104985. PubMed ID: 34237378
    [Abstract] [Full Text] [Related]

  • 19. Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.
    Schafer PH, Adams M, Horan G, Truzzi F, Marconi A, Pincelli C.
    Drugs R D; 2019 Dec 15; 19(4):329-338. PubMed ID: 31598889
    [Abstract] [Full Text] [Related]

  • 20. Apremilast in psoriatic arthritis.
    Schett G.
    Clin Exp Rheumatol; 2015 Dec 15; 33(5 Suppl 93):S98-100. PubMed ID: 26472278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.